Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD5 | P21918 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4540321 | 1.00 | HTR1A (0.46) | HTR1ACA9DRD1DRD2DRD5 | |
| SCHEMBL4534017 | 0.83 | HRH3 (0.53) | DRD1DRD2DRD5DRD3HRH3 | |
| SCHEMBL3657039 | 0.83 | SIGMAR1 (0.45) | HTR1AHRH3SIGMAR1 | |
| SCHEMBL4534013 | 0.83 | HRH3 (0.53) | DRD1DRD2DRD5DRD3HRH3 | |
| SCHEMBL3654484 | 0.81 | HRH3 (0.62) | HTR1ADRD2DRD3HRH3 | |
| SCHEMBL3654524 | 0.81 | HRH3 (0.62) | HTR1ADRD2DRD3HRH3 | |
| SCHEMBL3648509 | 0.80 | SIGMAR1 (0.64) | CA9DRD1DRD2DRD5DRD3 | |
| SCHEMBL4535003 | 0.77 | DRD2 (0.46) | DRD1DRD2DRD5DRD3 | |
| SCHEMBL4535006 | 0.77 | DRD2 (0.46) | DRD1DRD2DRD5DRD3 | |
| SCHEMBL3653389 | 0.77 | HRH3 (0.43) | HTR1ADRD3HRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101848896-A | Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists | WYETH CORP | 2010-09-29 | — | — | CN | disclosed |
| US-20090069300-A1 | ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069300-A1 | ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | HTR1A 52/4885CA9 4521/4885DRD1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.